Concurrently, mediastinal lymphadenopathy was observed. Given the suspicion of mediastinal lymphoma, a mediastinoscopy with lymph node biopsy was performed. Following a negative biopsy result, ...

Maplirpacept is under clinical development by Pfizer and currently in Phase II for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase II drugs for Primary Mediastinal B-Cell Lymphoma ...

CNTY-101 is under clinical development by Century Therapeutics and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase I drugs for Primary Mediastinal B-Cell ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

Dan Evans, 19, from Newark in Nottinghamshire, described his huge relief ringing the "cancer-free bell" at the teenage cancer ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

Just the word "cancer" is enough to fill many people with fright, but one 25-year-old has told Newsweek she is determined to show that a diagnosis—while incredibly challenging—need not mean death ...

Leukemias and lymphomas are often grouped together because they are both blood-related cancers that originate in lymphocytes. However, leukemia originates in the bone marrow and spreads through the ...

Objective—To determine if the 8 cm upper limit for mediastinal width applies in the trauma setting of today. To define the upper limit of normal mediastinal width for supine chest films. Methods—A ...

A chest computed tomography (CT) was remarkable for a large anterior mediastinal mass abutting the pericardium, which was deemed to most likely represent a germ cell tumor, although lymphoma could not ...

Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.